A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 (RAS Inhibitor) in Patients With MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer With RAS Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07897734

Title field or adapter rule

{'original_value': 'A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 (RAS Inhibitor) in Patients With MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer With RAS Mutation', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.870029+00:00

Published At

2026-10-27T00:00:00+00:00

Record Updated At

2026-10-27

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC", "RAS Mutation", "MTAP Deletion", "Lung Cancer", "Pancreatic Cancer Metastatic", "Thoracic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07897734"

protocolSection.identificationModule.officialTitle

"A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 (RAS Inhibitor) in Patients With MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer With RAS Mutation"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• PDAC (protocolSection.conditionsModule.conditions)
• PDAC - Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• NSCLC (protocolSection.conditionsModule.conditions)
• RAS Mutation (protocolSection.conditionsModule.conditions)
• MTAP Deletion (protocolSection.conditionsModule.conditions)
• Lung Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer Metastatic (protocolSection.conditionsModule.conditions)
• Thoracic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Dose Escalation PDAC', 'Dose Expansion 2L PDAC', 'Dose Expansion 2L or 3L NSCLC', 'Dose expansion 1L PDAC'], 'description': 'MTA-cooperative PRMT5 inhibitor', 'name': 'vopimetostat', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Dose Escalation PDAC', 'Dose Expansion 2L PDAC', 'Dose Expansion 2L or 3L NSCLC', 'Dose expansion 1L PDAC'], 'description': 'Pan-RAS molecular glue', 'name': 'ERAS-0015', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• vopimetostat (protocolSection.armsInterventionsModule.interventions[].name)
• ERAS-0015 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.